CCS Associates, Inc. (CCSA) is pleased to announce two new contracts with NIH Blueprint for Neuroscience Research Blueprint Neurotherapeutics Network.
CCSA will provide regulatory services consultation and advice to members of the NIH Blueprint for Neuroscience Research Blueprint Neurotherapeutics Network. The Blueprint Neurotherapeutics Network is helping small labs develop new drugs for nervous system disorders. The Network provides research funding, plus access to millions of dollars worth of services and expertise to assist in every step of the drug development process, from laboratory studies to preparation for clinical trials. Project teams across the U.S. have received funding to pursue drugs for conditions from vision loss to neurodegenerative disease to depression.
CCSA will also provide medical writing advice and services to members of the NIH Blueprint for Neuroscience Research Blueprint Neurotherapeutics Network. The Blueprint is a collaborative framework that includes the NIH Office of the Director and the NIH Institutes and Centers that support research on the nervous system. By pooling resources and expertise, the Blueprint identifies cross-cutting areas of research and confronts challenges too large for any single Institute or Center. Since its inception in 2004, Blueprint has supported the development of new tools, training opportunities and other resources to assist neuroscientists. In 2009, the Blueprint Grand Challenges were launched to catalyze research with the potential to transform our basic understanding of the brain and our approaches to treating brain disorders.
CCSA is a woman-owned, small business providing leading-edge scientific advisory services in pharmaceutical and device discovery and development to government agencies as well as pharmaceutical and biotech industries.